Quick summary
Semax is a synthetic ACTH(4-10) fragment approved in Russia as a prescription nootropic. It boosts BDNF and NGF expression, enhances cognition without stimulant side effects, and has demonstrated neuroprotective benefits in stroke recovery studies.
Overview
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the 4–10 fragment of adrenocorticotropic hormone (ACTH), extended with a C-terminal Pro-Gly-Pro sequence to improve metabolic stability. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences beginning in the 1980s and officially registered with the Russian Ministry of Health in 2011 as a prescription drug under the INN 'semax.' Russia and Ukraine currently approve it for acute ischemic stroke, chronic cerebrovascular insufficiency, cognitive and memory disorders, peptic ulcer disease, and optic nerve atrophy — a breadth of indication reflecting decades of state-funded research largely unavailable in Western scientific literature.
Three primary variants exist. Standard Semax (the base heptapeptide) has a plasma half-life of approximately 2–3 minutes due to rapid aminopeptidase cleavage; it relies on quick CNS uptake via intranasal delivery to produce downstream effects that persist for hours despite the peptide itself being cleared within minutes. N-Acetyl Semax adds an acetyl group to the N-terminus, conferring 3–5× greater resistance to enzymatic degradation and a meaningful extension of effective half-life. N-Acetyl Semax Amidate (NASemax-A) additionally replaces the C-terminal carboxyl group with an amide — a modification that confers the most potent BDNF-inducing effects in preclinical models and is regarded by the research community as the highest-potency variant, though it is not the registered pharmaceutical form in Russia.
Western regulatory status is research-only: Semax is not FDA-approved, not a scheduled substance under the US Controlled Substances Act, and not subject to WADA anti-doping restrictions. This has made it accessible through research peptide suppliers, though product quality varies widely without compounding pharmacy oversight. The Russian pharmaceutical-grade product (Semax nasal solution 0.1% and 1%) remains the reference standard against which preclinical and clinical research was conducted.
The cognitive profile of Semax is frequently described as 'clean' — focused attention, improved working memory, and faster mental processing without the jitteriness, cardiovascular stimulation, or post-dose crash associated with amphetamines, racetams, or caffeine. This is consistent with its predominantly neurotrophic and monoaminergic mechanism rather than direct catecholamine release. Users report subjective effects within 15–30 minutes of intranasal dosing that persist 4–8 hours, with cycle lengths of 10–14 days being standard in Russian clinical practice.
Mechanism of action
Semax's cognitive and neuroprotective effects emerge from convergent actions on monoaminergic neurotransmission and neurotrophic factor expression. At the neurotransmitter level, Semax acutely activates serotonergic and dopaminergic systems in limbic and cortical circuits. Dolotov et al. (Neurosci Lett, 2006) demonstrated that Semax administration raised hippocampal 5-hydroxyindoleacetic acid (5-HIAA, the primary serotonin metabolite) to approximately 180% of baseline within 1 hour — a finding consistent with the subjective anxiolytic-plus-focusing quality users describe. Dopaminergic activation in the prefrontal cortex and striatum contributes to improved executive function and working memory, without the receptor downregulation or rebound that accompanies direct dopamine-releasing agents.
The BDNF axis represents Semax's most distinctive and durable mechanism. BDNF (brain-derived neurotrophic factor) is the primary growth factor supporting hippocampal neurogenesis, dendritic spine density, and long-term potentiation — the cellular substrate of learning and memory. Mironova et al. (Brain Res, 2007) quantified BDNF mRNA and protein in rat hippocampus following Semax administration, finding increases of 50–200% above baseline peaking at 1–3 hours post-dose, with elevation persisting for 24+ hours after the peptide itself had been cleared. This dissociation — rapid clearance of the peptide, prolonged elevation of the effector molecule — is the mechanistic explanation for Semax's clinical dosing cycles: even short courses induce sustained neuroplastic adaptations that outlast the drug's pharmacokinetic window. TrkB (the high-affinity BDNF receptor) expression is also upregulated by Semax, amplifying the sensitivity of target neurons to endogenous BDNF.
In ischemic and hypoxic contexts, Semax provides neuroprotection through multiple mechanisms: reduction of pro-inflammatory cytokine release (IL-1β, TNF-α), attenuation of glutamate-mediated excitotoxicity, and upregulation of antioxidant defense pathways. Sokolova et al. (2024) demonstrated in a middle cerebral artery occlusion (MCAO) rat model that intranasal Semax reduced infarct volume, improved neurological deficit scores, and decreased markers of oxidative damage versus saline-treated controls. The intranasal route achieves CNS bioavailability via olfactory epithelium transcytosis and perineural transport along the olfactory nerve, with approximately 0.093% of intranasal dose reaching brain tissue within 2 minutes — sufficient for pharmacological activity given the picomolar-to-nanomolar affinity of Semax for its receptors.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| cognitive enhancement | nasal | 200–600 mcg | 2-3x daily | Nasal spray is standard. Start at 200mcg. Available in 0.1% and 1% solutions in Russia. Cycles of 10-20 days. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
The clinical evidence base for Semax is predominantly Russian-language and concentrated in stroke and cognitive disorders research. The most substantial published study is a 110-patient randomized controlled trial of intranasal Semax in acute ischemic stroke (PMID 29798983), in which patients received two 10-day courses of 6,000 mcg/day intranasal Semax versus placebo. Semax-treated patients showed significantly better outcomes on the Barthel Index of activities of daily living and the NIH Stroke Scale at 30-day follow-up, with the effect size most pronounced in patients treated within the first 6 hours of symptom onset. Gusev et al. (1996) conducted earlier open-label work in 180 ischemic stroke patients demonstrating reduced neurological deficit and accelerated functional recovery.
In the realm of cognitive neuroscience, Zhurnal Nevrologii i Psikhiatrii (1999; PMID 10358912) published a study of Semax in patients with mild cognitive impairment secondary to cerebrovascular disease, finding statistically significant improvements in attention, short-term memory, and processing speed after a 10-day 900 mcg/day intranasal course versus placebo. These improvements were maintained at 30-day follow-up, consistent with the BDNF-mediated neuroplasticity mechanism rather than transient stimulant effects.
At the molecular level, Mironova et al. (Brain Res, 2007; PMID 16996037) provided the most rigorous quantification of Semax's neurotrophic action: BDNF mRNA in rat hippocampal CA1 and CA3 regions increased 50–200% above baseline within 1–3 hours of a single intranasal Semax dose (50 mcg/kg), with protein-level increases measured by ELISA confirming the transcriptional data. Dolotov et al. (Neurosci Lett, 2006; PMID 16362768) similarly quantified serotonergic activation, finding 5-HIAA elevations to ~180% of baseline in limbic structures — providing the mechanistic substrate for the anxiolytic-cognitive synergy users report.
Pharmacological comparison of administration routes (intranasal vs. intraperitoneal) was characterized by PMID 21268834, confirming that intranasal delivery achieves meaningful CNS bioavailability within minutes via olfactory transcytosis, validating the standard clinical route. The acetylated variants were characterized by Kozlovskaya et al. (2016; PMID 27586814), which established that N-acetylation improves enzymatic resistance approximately 3–5× and enhances BDNF-inducing potency, with the amidate variant showing the strongest neurotrophic signal in both in vitro and in vivo models.
The primary limitation of the Semax evidence base is that nearly all clinical trials were conducted in Russia under regulatory frameworks that differ from FDA or EMA standards, with variable blinding and outcome reporting quality by contemporary standards. Independent replication in Western academic settings is essentially absent, meaning the research literature — while substantial in volume — carries higher uncertainty than equivalent Western Phase II/III trial data. Anecdotal user reports from biohacking communities are consistent with the documented BDNF and monoaminergic mechanisms but cannot substitute for controlled evidence.[1][2][3][4][5][6]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Semax for synergistic effects.
Legal status
Approved as a prescription drug in Russia and Ukraine. Not FDA-approved. Available as a research peptide in the US. Not scheduled.
Sourcing & access
Research compound
Semax is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, extended with a Pro-Gly-Pro sequence for metabolic stability. It was developed at the Russian Academy of Sciences in the 1980s and registered with the Russian Ministry of Health in 2011. It is approved in Russia and Ukraine for stroke recovery, cognitive disorders, optic nerve atrophy, and peptic ulcer disease — giving it one of the most diverse approved indication sets of any nootropic peptide.
Semax operates through two primary mechanisms: it acutely activates serotonergic and dopaminergic circuits (raising hippocampal serotonin metabolites to ~180% of baseline within 1 hour), and it induces sustained BDNF and NGF upregulation — elevating BDNF mRNA 50–200% above baseline, with increases persisting 24+ hours after the peptide itself has been cleared. This BDNF-driven neuroplasticity is the likely explanation for the 'clean' cognitive enhancement users describe: improved working memory, attention, and learning speed without stimulant side effects.
Standard Semax has a plasma half-life of ~2–3 minutes due to rapid aminopeptidase degradation. N-Acetyl Semax adds an acetyl group to the N-terminus, conferring ~3–5× greater enzymatic resistance and a longer effective half-life. N-Acetyl Semax Amidate (NASemax-A) additionally amidates the C-terminus — the modification associated with the strongest BDNF-inducing potency in preclinical models. NASemax-A is regarded as the highest-potency variant but is not the registered pharmaceutical form in Russia.
Intranasal is the standard and clinically validated route. Semax is rapidly degraded in plasma (~2–3 min half-life), so subcutaneous injection delivers most of the peptide systemically before it can cross the blood-brain barrier. Intranasal delivery bypasses this by transporting the peptide directly along olfactory nerve fibers to the CNS, achieving brain concentrations within 2 minutes of administration. Research peptide users who inject subcutaneous Semax are likely getting suboptimal CNS delivery relative to the nasal route.
The key trial (PMID 29798983) randomized 110 ischemic stroke patients to two 10-day courses of 6,000 mcg/day intranasal Semax versus placebo. Semax recipients showed significantly better Barthel Index (activities of daily living) and NIH Stroke Scale scores at 30 days, with the greatest benefit in patients treated within 6 hours of onset. Earlier open-label work by Gusev et al. (1996) in 180 stroke patients also demonstrated reduced neurological deficit and faster functional recovery.
Semax modulates dopaminergic activity indirectly rather than acting as a direct dopamine releaser or reuptake inhibitor. It activates serotonergic circuits that cross-regulate dopamine, and upregulates BDNF, which supports dopaminergic neuron survival and function. The result is improved prefrontal dopaminergic tone without the receptor downregulation or rebound that follows direct dopamine-releasing agents (amphetamines) or reuptake inhibitors.
Semax is not approved for depression or anxiety but has a mechanistic basis for effects in both domains. Serotonin activation at ~180% of baseline (Dolotov et al. 2006) is pharmacologically comparable to effects of SSRIs, though the kinetics are quite different (acute vs. chronic). BDNF upregulation is the target of most antidepressant research. Russian clinical literature includes some anecdotal and small-study reports of mood improvement in patients with cerebrovascular disease. User reports in Western biohacking communities frequently describe anxiolytic-adjacent and mood-brightening effects.
Semax is not FDA-approved, not a scheduled substance under the Controlled Substances Act, and not banned by WADA. It exists in a regulatory gray area: legal to possess and purchase as a research chemical, but not legal to prescribe, sell for human consumption, or import for clinical use. The practical enforcement risk for individual research use is extremely low, but quality control is a legitimate concern given the absence of pharmaceutical-grade oversight in US-available products.
Cognitive effects are typically noticed within 15–30 minutes of intranasal administration and persist for 4–8 hours — far longer than the peptide's 2–3 minute plasma half-life, because downstream BDNF and monoaminergic effects outlast the molecule itself. With repeated dosing over a 10–14 day cycle (standard in Russian clinical practice), cumulative BDNF-driven neuroplasticity effects may extend benefits beyond the active dosing period. Most users report that effects are subtle on day 1 and build progressively over the first week.
In Russia, Semax is prescribed in hospital and outpatient settings for acute ischemic stroke (administered within hours of onset for maximal neuroprotection), recovery from TBI, and chronic cerebrovascular insufficiency. Standard protocols use 0.1% or 1% nasal solutions at doses of 600–6,000 mcg/day in cycles of 10–14 days, sometimes repeated. It is considered a first-line adjunct in neurological recovery rather than a lifestyle nootropic — a framing that contrasts with its predominant use in Western biohacking contexts.
Research references
- Semax, an Analog of ACTH(4-10) with Cognitive Effects, Regulates BDNF and trkB Expression in the Rat HippocampusPubMed
- Semax, an ACTH(4-10) Analogue with Nootropic Properties, Activates Dopaminergic and Serotoninergic Brain Systems in RodentsPubMed
- The Neuroprotective Effects of Semax in Conditions of MPTP-Induced Lesions of the Brain Dopaminergic SystemPubMed
- The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic StrokePubMed
- Semax, an Analog of ACTH(4-7), Regulates Expression of Immune Response Genes During Ischemic Brain Injury in RatsPubMed
- Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndromePubMed